Group items tagged

wo classes of proposals will be considered in response to this solicitation: Research Proposals describing collaborative research projects, and Data Sharing Proposals to enable sharing of data and other resources. Domestic and international projects will be considered. As detailed in the solicitation, international components of collaborative projects may be funded in parallel by the participating agencies. Specific CRCNS opportunities for parallel funding are available for bilateral US-German Research Proposals, US-German Data Sharing Proposals, US-French Research Proposals, US-French Data Sharing Proposals, US-Israeli Research Proposals, US-Israeli Data Sharing Proposals, US-Japanese Research Proposals, US-Japanese Data Sharing Proposals, US-Spanish Research Proposals, US-Spanish Data Sharing Proposals, and multilateral proposals involving the United States and two or more CRCNS partner countries (please see Section VIII of the solicitation for country-specific instructions and limitations).

The US National Science Foundation (NSF) and the US-Israel Binational Science Foundation (BSF) have signed a Memorandum of Understanding (MOU) on Research Cooperation. The MOU provides an overarching framework to encourage collaboration between US and Israeli research communities and sets out the principles by which jointly supported activities might be developed. The MOU provides for an international collaboration arrangement whereby US researchers may receive funding from the NSF and Israeli researchers may receive funding from the BSF. The Division of Molecular and Cellular Biosciences (MCB) the Directorate for Biological Sciences (BIO) of the National Science Foundation and the US-Israel Binational Science Foundation are pleased to announce a US-Israel collaborative research opportunity. The goal is to help reduce some of the current barriers to working internationally. NSF/BIO/MCB and BSF will address these issues by allowing US and Israeli researchers to submit a single collaborative proposal that will undergo a single review process.

As a key activity, INL promotes the development of substance use disorder studies programs at universities around the world to further develop a trained professional workforce for prevention, treatment and recovery programs. In addition, INL encourages applied research to assess the effectiveness of drug demand reduction efforts, advocates government and community support for evidence based drug demand reduction programs, and fosters the development of a worldwide network including professionals and academic experts focused on drug use. The purpose of this project is to promote the creation and networking of substance use disorder studies researchers and programs in universities in Latin America and the Caribbean, Asia and the Pacific, Africa and Eastern Europe. The recipient will also support existing drug use studies programs with technical assistance and mentoring of program directors. In addition, the recipients will advocate for government use of evidence based substance use disorder prevention programs and treatment as well as work towards applied research to advance the substance use disorder field for prevention, treatment and recovery.

Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.

Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.

The National Institute on Aging is seeking applications on systems biology approaches using non-mammalian laboratory animal models to increase our understanding of the basic biology underpinning neurodegeneration. It is expected that research supported under this FOA will provide new insights into molecular networks that might be involved in causing, amplifying or protecting against neurodegeneration, and that, in turn, might ultimately contribute to Alzheimer's disease or related dementias. Importantly, a major goal of this FOA is to use interaction and regulatory networks produced and analyzed using systems biology to gain these new insights. Because this FOA is directed toward discovery, currently employed genetically modified laboratory animals used to study AD are not required, although they may be used. Because this FOA requires systems biology approaches, data used to build interaction or regulatory networks may also come from humans or other mammals in which AD, related dementias, or aging-related cognitive decline have been observed. This FOA will only support studies using non-mammalian laboratory animal models; studies involving humans or experiments with mammals will not be allowed under this FOA.

NIDILRR proposes to fund two Disability and Rehabilitation Research Projects of three years each to conduct research on opioid use disorder among people with disabilities. Each grant will be funded up to $500,000. Topic of interest include: 1) Systematic review of existing literature on opioid-use disorder and people with disabilities; 2) Prevalence estimates and patterns of opioid use disorder treatment for people with disabilities; 3) Factors associated with increased risk for opioid use disorder; 4) Factors associated with improved access to treatment for opioid use disorder; 5) Interventions that contribute to improved outcomes; and 6) Effects of government policies and programs on access to treatment for people with disabilities who have opioid-use disorders.

The OPORP Orthotics and Prosthetics Outcomes Research Award (OPORA) is being offered for the first time in FY14. It is intended to support research that evaluates the comparative effectiveness of and functional outcomes associated with prosthetic and orthotic clinical interventions and/or other rehabilitation interventions for Service Members and Veterans who have undergone limb salvage or limb amputation. The goal is to improve our understanding of and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers. Proposed projects should be designed to provide outcomes data regarding orthotic and prosthetic devices, and/or related clinical interventions and must include the anticipated effect on patient care metrics. Collaboration with military researchers and clinicians is encouraged, as are joint Department of Defense (DoD)-VA studies, including longitudinal outcome studies. Studies are sought that: * Compare different patient care approaches. * Include patient-centric outcome assessments. * Have the potential to generate new knowledge that can be developed into new clinical practice guidelines, and/or new prescription algorithms for prosthetic and orthotic devices. * Have the potential to develop new technology for improved prosthetic and orthotic devices, therefore improving patient outcomes. * Provide information on quality of life, reintegration, and/or return to duty/return to work as it pertains to those patients who use a prosthetic or orthotic device due to limb trauma. All applications must demonstrate direct relevance to Service Members and Veterans with traumatic extremity injury and/or amputation using prosthetics and orthotic devices. Examples of studies that are appropriate for submission to the FY14 OPORA include, but are not limited to, examination of the

Stem cell technology holds the promise of providing a nearly limitless source of safe, immune-matched cells for clinical use. One of the first areas where this promise can be realized is through cell products that lack a nucleus and thus face fewer regulatory hurdles, such as red blood cells and platelets. Considerable progress has been made but scientific questions remain and improved tools to enhance the production are required if translation to clinical use is to be achieved. To this end, this FOA will support research addressing remaining scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics. While production of sufficient numbers of cells such as platelets and red cells has been demonstrated using cellular engineering methods, basic research questions related to cell differentiation and maturation remain, which if elucidated, may allow for the development of new ways to efficiently produce clinically-useful stem cell-derived platelets or red blood cells. In addition to this FOA, two companion FOAs (RFA-HL-15-029 and RFA-HL-15-030) will support small business research to develop improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner.

"Solicitation of Proposals to Conduct Research Using Microgravity Simulation Devices" NASA Research Announcement (NRA) Appendix D - NNH16ZTT001N-MS NRA This National Aeronautics and Space Administration Research Announcement: "Solicitation of Proposals to Conduct Research Using Microgravity Simulation Devices" is an Appendix to the NASA Omnibus Research Announcement ROSBio-2016 (NNH16ZTT001N NRA). This Appendix solicits proposals that will use microgravity simulation devices to test specific hypotheses regarding the effects of altered gravity on biological systems, including cells, tissues, microorganisms, plants, and whole organisms. Proposing investigators will have the option of using the Microgravity Simulation Support Laboratory (MSSL) at the Kennedy Space Center, or using microgravity simulation devices at other locations. Proposals must address Space Biology research emphases, visions, and goals identified in the ROSBio-2016 Omnibus NRA or in the Space Biology Science Plan 2016-2025, and/or recommendations from the Decadal Survey.

This FOA solicits development of innovative adaptations of existing technologies to enable their use for readily identifying, manipulating, or analyzing glycans and their biological binding partners. This may encompass the adaptation of commonly used laboratory-based or computational tools to enable their facile application to glycoscience for the first time, as well as the adaptation of tools presently used by specialists in glycoscience to make them significantly more straightforward and accessible for non-specialists. It is possible that a project might simplify a current specialized approach by migrating it to a more commonly used platform, developing automation for data acquisition and interpretation, or redesigning the present tool to make it easier to use. This announcement differs from the related FOA RFA- RM-16-022 which solicits new or more effective tools or technologies, thus representing an expansion of existing technologies.

The National Institute on Drug Abuse (NIDA) intends to publish a series of Funding Opportunity Announcements (FOA) for Cooperative Agreements to solicit applications for a network of researchers collaborating across justice and community-based service settings to transform community-level responses to opioid misuse and opioid use disorder in justice-involved populations. Opioid misuse and opioid use disorder consequences exist at the intersection of health and justice systems. Improving the capacity of the justice system to respond to opioid crisis with evidence-based approaches that include the use of medications for OUD requires strong partnerships between justice systems and healthcare as well as other community based organizations. Supporting the development of these relationships and novel models of justice-healthcare and other community collaborations is a critical target in addressing the current opioid crisis. NIDA is interested in launching a network of investigators who can rapidly conduct research to address the opioid crisis in justice settings. A variety of research methods will be used, including clinical trials, implementation science research, policy evaluations and/or modeling approaches. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects. This FOA is expected to use a multicomponent cooperative agreement mechanism. The FOA is expected to be published in October 2018 with an expected application due date in December 2018.

This Funding Opportunity Announcement encourages developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Research is encouraged to incorporate recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population. PA-18-651 uses the R01 grant mechanism, PA-18-652 uses the R21 mechanism, while PA-18-653 uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using the R01 mechanism. Applicants wanting to develop and pilot test an intervention may wish to apply using the R34 mechanism. Also listed under R21

This Funding Opportunity Announcement encourages developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Research is encouraged to incorporate recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population. PA-FY-NNN uses the R01 grant mechanism, PA-FY-NNN uses the R21 mechanism, while PA-FY-NNN uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using the R01 mechanism. Applicants wanting to develop and pilot test an intervention may wish to apply using the R34 mechanism.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

Long-term misuse and chronic exposure to abused substances can produce widespread changes in brain structure and function. Although much progress has been made, additional research is still needed to identify the neurobiological changes that result from substance use, and how these changes contribute to substance use disorders. The overarching goals of the research areas described in this FOA are to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence, withdrawal, and relapse to chronic substance use. An understanding of the basic mechanisms underlying substance use disorders can help to identify targets for prevention and treatment interventions. Research utilizing basic, translational, or clinical approaches is appropriate.

VentureWell, with the support from the Whitaker International Program, is implementing a new grants program, BME-IDEA International: Developing Global Connections for US-based BME Design Faculty and Students. The BME-IDEA International grants program will support collaborative project opportunities for US-based BME design students and faculty across the BME-IDEA global network and will connect faculty members of the consortium to share resources, best practices, ideas, curriculum, knowledge, challenges, and opportunities around innovation in BME design. The two goals of the BME-IDEA International grants program are to: 1) Build strong partnerships between US-based and global BME design and innovation programs, including exchanges of faculty, students, resources, and best practices. 2) Foster the development of US-trained leaders in BME design and innovation who understand the challenges of teaching and practice in this field around the world, especially in low- and middle-income countries (LMIC) in Africa and Latin America. Faculty Grants: Grants of up to $4,000 will be awarded to US-based faculty for global project explorations and/or experiences to enhance their professional development and knowledge base within the field of biomedical design and innovation.  Student Grants: Grants of up to $9,000 will be awarded to student teams for the development and implementation of BME projects focused on innovation, design, and entrepreneurship.

The goal of this funding announcement is to establish a sustainable network of US institutions that can obtain hospitalization data and provide accurate estimates of annual influenza vaccine effectiveness (VE) to preventinfluenza-associated hospitalizations in US adult populations. Participating institutions will coordinate enrollment of adult hospitalized patients with acute respiratory illness (ARI), confirm influenza infection using sensitive laboratory-based molecular assays, and estimate VE using a test-negative study design.

The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations to develop and implement the use of 3D biofabricated tissue models as novel drug screening platforms and advance pre-clinical discovery and development of non-addictive treatments for nociception, opioid use disorder (OUD) and/or overdose. In particular, support during the UH2 phase is for the application of 3D biofabrication technologies to develop novel multicellular tissue constructs for drug screening by using human iPSC-derived cells representing sensory/pain neurons, brain regions, and other tissues involved in nociception, addiction and/or overdose, including tissue models of the blood-brain barrier (BBB). Support during the UH3 is for implementation of drug screens using the 3D tissue models developed during the UH2 phase. Please limit this field to a brief description of to page in length. Brevity is appreciated. This FOA is part of the of the NIHs Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative

The purpose of this funding announcement (FA) is to solicit applications for Genome Centers to generate and process genomic data as part of the All of Us Research Program. The All of Us Research Program seeks to create one of the world's largest and most comprehensive precision medicine research platforms with a data resource containing multi-layered data on one million or more participants. The All of Us Genome Centers will generate both genotype and whole genome sequence data from biospecimens from this cohort. These Centers also will operate an analysis workflow resulting in high-confidence calling of all variant types (single nucleotide variants, small insertions/deletions, larger structural variants including copy number variations) and establish a robust pipeline to securely transfer data to the All of Us Data and Research Center